Company news

Palisade Bio, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025

March 12, 2025

Palisade Bio Participates in Virtual Investor “What This Means” Segment

March 4, 2025

Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada’s SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)

February 20, 2025

Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

February 19, 2025

Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis

February 9, 2025

Palisade Bio Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis

January 15, 2025

Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

January 2, 2025

Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board

December 16, 2024

Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

December 11, 2024

Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects

December 2, 2024

Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)

November 20, 2024

Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108

November 11, 2024

Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC)

November 6, 2024

Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis

October 30, 2024

Palisade Bio Announces Abstract Accepted for Presentation at the American College of Gastroenterology’s (ACG) 2024 Annual Scientific Meeting

October 14, 2024

Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)

October 9, 2024

Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis

September 24, 2024

Palisade Bio Launches New Corporate Branding and Reiterates Commitment to Advancing Next-Generation Precision Therapies

September 15, 2024

Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be Utilized as a Potential Marker for Patient Stratification

September 4, 2024

Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

August 12, 2024

Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis

August 7, 2024

Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108

July 28, 2024

Palisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108

July 18, 2024

Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product

July 10, 2024

Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences

June 20, 2024

Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108

June 10, 2024

Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models

May 20, 2024

Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update

May 13, 2024

Palisade Bio Appoints Margery Fischbein to its Board of Directors

May 6, 2024

Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules

May 1, 2024

Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)

April 30, 2024

Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach

April 22, 2024

Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool

April 15, 2024

Palisade Bio Announces 1-for-15 Reverse Stock Split

April 2, 2024

Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update

March 26, 2024

Palisade Bio Provides Corporate Update and Reiterates Guidance

February 12, 2024

Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders

February 7, 2024

Palisade Bio Announces Exercise of Previously Issued Warrants for $2.5 Million

January 29, 2024

Palisade Bio Announces Positive Preclinical Data of Lead Program PALI-2108 at the 2024 Crohn’s & Colitis Congress

January 28, 2024

Palisade Bio Selected for Poster Presentation at the 2024 Crohn’s & Colitis Congress

January 8, 2024

Palisade Bio Announces Receipt of Second Milestone Payment from the US Crohn’s and Colitis Foundation for Development of PALI-2108

December 27, 2023

Palisade Bio Reports Third Quarter 2023 Financial Results and Provides Business Outlook

November 9, 2023

Palisade Bio Appoints GI Clinical Expert and Biotech Entrepreneur Mitchell Jones, M.D., Ph.D. as Chief Medical Officer

September 10, 2023

Palisade Bio Announces Closing of $2 Million Registered Direct Offering Priced At Market Under Nasdaq Rules

September 10, 2023

Palisade Bio Announces $2 Million Registered Direct Offering of Common Stock Priced At Market Under Nasdaq Rules

September 6, 2023

Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement with Giiant Pharma, Inc. for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease

September 5, 2023

Palisade Bio Reports Second Quarter 2023 Financial Results

August 10, 2023

Palisade Bio Announces Topline Results from U.S. Phase 2 PROFILE Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions

August 8, 2023

Palisade Bio Announces Completion of Enrollment in LB1148 Dose Optimization Study

July 4, 2023

Palisade Bio Promotes J.D. Finley to Chief Executive Officer

May 31, 2023

← Newer news releases · Older news releases →

Decks

The 5 newest of 42 decks. Every deck is listed under its year.